Controle da hipertensão arterial após bypass gástrico em Y-de-Roux em obesos diabéticos by Cazzo, E. et al.
ARQGA/1693
AR
TIG
O O
RI
GI
NA
L /
 OR
IG
IN
AL
 AR
TIC
LE
 
v. 51 no. 1 - jan./mar. 2014   Arq Gastroenterol 21
INTRODUCTION
Essential hypertension is a disorder commonly 
observed in general practice. Its association with 
type 2 diabetes mellitus (T2DM) is widely recognized 
and it was already reported that 40% to 80% of  all 
diabetic patients may probably be hypertensive as 
well(3, 26). As a result of  impaired autonomic func-
tion and extensive organ damage, higher blood 
pressure variability, marked orthostatic responses 
and impaired nocturnal blood pressure reductions 
are common features in diabetic individuals(26). It is 
postulated that there is a substantial interconnec-
tion between metabolic factors and hypertension, 
beyond what we comprehend at the moment(4, 20). 
The underlying pathophysiology of  this interplay is 
yet to be understood, however increasing evidence 
regarding this topic is emerging. Among nondiabetic 
hypertensive patients, poor blood pressure control 
is associated with two fold increased risk of  dia-
betes(4, 20). The benefits of  reducing blood pressure 
in diabetic patients have been clearly shown by the 
results of  the Hypertension Optimal Treatment(13) 
and United Kingdom Prospective Diabetes Study(30) 
studies among others(7, 8, 10, 14, 29). Diabetic patients 
may require more intense treatment to achieve the 
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same blood pressure levels as nondiabetic individu-
als(18). Adhesion to long term nonpharmacological 
and drug treatments constitute a point of  concern 
once there are reports showing consistently low rates 
of  complete adherence to both, especially in poorly 
developed regions(30). Surgery for morbid obesity has 
become a standard treatment option leading to mark-
edly lower morbidity(22). Global impact of  surgery 
on long term mortality reduction has already been 
observed on obese patients with 40% reduction on 
all causes mortality, 56% on coronary heart disease, 
92% on diabetes complications and 60% on any type 
of cancer(1). Improvement of metabolic comorbidites 
is observed early after surgery and it is not completely 
comprehended(22, 23). It is known that most bariatric 
procedures lead to increased level of  gastrointestinal 
hormones called incretins that raise insulin sensitiv-
ity. This mechanism is probably reinforced by late 
weight loss(23).
This study aims to describe hypertension evolution 
after Roux-en-Y gastric bypass in patients with T2DM.
METHODS
This study is descriptive and longitudinal and 
designed as a retrospective cohort. It included obese 
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subjects which had T2DM according to American Diabetes 
Association (ADA) criteria who were submitted to open 
Roux-en-Y gastric bypass (RYGB) at Hospital de Clinicas 
– Unicamp between 2000 and 2010. This study was submit-
ted and approved by the local Research Ethics Committee. 
Surgery was indicated based on the National Institutes of 
Health Consensus Statement criteria(12). Sample size esti-
mation was performed through single proportion formula 
with 95% confidence interval(5). Precision was set at 10% 
and the calculated sample size was 84. Exclusion criteria 
for this study were: individuals who had undergone other 
bariatric procedures after RYGB, whose postoperative 
follow-up time was less than 12 months, and who belonged 
to vulnerable groups (mentally ill, institutionalized or aged 
under 18 years old).
From 672 subjects who underwent RYGB, 90 who filled 
criteria for both T2DM as specified by American Diabetes 
Association(2) and hypertension according to Brazilian 
guidelines(25), and had been followed for at least 12 months 
were included. Main characteristics regarding demograph-
ics, presence of  hypertension, and preoperative pharmaco-
logical treatments were assessed. Anti-hypertensive usage 
before and after surgery were evaluated. Comparisons were 
made between the periods immediately before and at least 
one year after surgery, in order to measure the impact of 
the procedure on resolution of  T2DM and hypertension. 
Some biochemical characteristics were evaluated included 
fasting glucose, fasting insulin, hemoglobin A1c, homeo-
stasis model assessment – insulin resistance (HOMA-IR) in 
order to identify correlations with hypertension resolution 
or improvement. Hypertension resolution was achieved 
through three non-consecutive measures below 130/85 
mmHg(25). T2DM resolution was achieved according to 
American Diabetes Association criteria (FG < 100 mg/dL 
and HbA1c ≤6,5%)(2).
Statistical Analysis
The baseline characteristics of  patients are described 
and then compared with postoperative period. Data were 
examined for normality according to the Pearson’s chi-
squared test. For univariate analysis of categorical variables, 
chisquare and Fisher’s exact tests were carried out. The Mc-
Nemar test was used for comparison of proportions between 
the two periods. To identify possible factors associated to the 
studied outcomes it was used the multiple logistic regression 
analysis. The significance level adopted was 5% (P-value 
<0.05). For execution of analysis it was used Statistic Analy-
sis System (SAS) software for Windows version 9.2.
RESULTS
Of 90 patients selected for study, 69 (76.7%) were female 
and 21 (23.3%) were male. The mean age at surgery was 46 
(range, 22-64) years. The mean postoperative and follow-up 
time was 35.1 (range 12-120) months. Main subject charac-
teristics at baseline are summarized on Table 1.
Mean hospital stay was 4.2 } 0.3 days. Overall surgical 
morbidity was 11.1% and the main complications were 
wound infection (4,4%) and atelectasis (2.2%). There was 
no mortality.
Patients experienced a significant decrease of body mass 
index from 44.5 } 8.8 kg/m2 to 31.7 } 7.9 kg/m2 (P<0.001). 
Mean weight loss was 29.7 } 9.3 kg (P<0.0001). Percentage 
of  excess weight loss after surgery was 71.5 } 27.7%. Pre-
operatively, 100% patients had hypertension. After surgery, 
there were 13 (14.4%) who still had hypertension, leading to 
a resolution rate of 85.6% (P<0.0001).
There was a markedly reduction on anti-hypertensive 
classes usage after surgery from 1.6 (range, 1-4) to 0.5 
(range, 0-2) drug (P<0.0001). Among patients who did not 
achieve hypertension resolution it was observed significant 
reduction on number of  anti-hypertensive classes usage, 
from 2.3 before to 1.3 after surgery (P = 0.001). Mean 
resolution time was 3.2 months (range, 1-12). According to 
multivariate analysis, the factors statistically associated to 
hypertension resolution were: HOMA – IR (P = 0.0482), 
postoperative body mass index (P = 0.0017), hypertension 
duration (P = 0.0321), preoperative fasting insulin (P = 
0.0385), number of  preoperative anti-hypertensive classes 
(P = 0.0072), number of  postoperative antihypertensive 
classes (P = 0.0002) and percentage of  excess weight loss 
(P = 0.0011). Table 2 shows resolution rates varied accord-
ing to hypertension severity grade as classified by Brazil-
TABLE 1. Subject characteristics at baseline
Gender
    Male
    Female
23.3%
76.7%
Age 46 ± 10.8 yrs
BMI 44.4 ± 8.9 (35-80.8) kg/m2
Weight (kg) 102.9 ± 18.7 (72-180) kg
Postoperative follow-up 34.8 ± 25.7 months
Comorbidities
    Hypertension
    T2DM
    Dyslipidemia
100%
100%
87.8%
Pharmacological treatments
    Insulin
    Oral Hypoglycemiants
    Anti-lipids
    Anti-hypertensive
21.1%
98.9%
76.7%
100%
TABLE 2. Resolution of Hypertension according to preoperative severity 
grade
Severity grade N (%) Resolution (%)
I 34 (37.8) 34 (100)
II 40 (44.4) 33 (82.5)
III 16 (17.8) 10 (62.5)
Total 90 (100) 77 (85.6)
N: number of patients
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ian guidelines(25). Resolution rates stratified according to 
preoperative number of anti-hypertensive classes are shown 
on Table 3.
TABLE 3. Resolution of Hypertension according to number of preopera-
tive anti-hypertensive classes
Anti-hypertensive classes N (%) Resolution (%)
1 28 (31.1) 28 (100)
2 36 (40) 35 (97.2)
3 17 (18.9) 11 (64.7)
4 9 (10) 3 (33.3)
Total 90 (100) 77 (85.6)
N: number of patients
Before surgery, all patients had T2DM. Postoperatively 
nine (10%) still had it. Its resolution rate was 90% (P<0.0001). 
Analyzing hypertension resolution along with diabetes it 
was observed that 77.8% experienced resolution of  both 
disorders, 12.2% had only diabetes resolution, 7.8% had only 
hypertension resolution and 2.2% had none. The association 
between resolution of both comorbidities were not statisti-
cally significant (P = 0.6127).
DISCUSSION
There is clear evidence about the great benefits of RYGB 
on hypertension and T2DM, especially when compared to 
the effectiveness of clinical treatment(23, 24). It is known that 
this operation brings this impact through a complex array 
of metabolic mechanisms which involve increased incretin 
secretion due to duodenal exclusion or early arrival of nu-
trients on ileum; weight loss; decreased hepatic uptake of 
lipids; and changes on adipocin profile(17, 23, 28).
This study showed a high hypertension resolution rate 
(85.6%) among previously diabetic patients. T2DM resolu-
tion was also high (90.6%) although both resolutions were 
not statistically linked. This may be caused by the multifac-
torial nature of both disorders and the intrincate pathways 
by which they are associated(3, 20, 26). A metanalysis involving 
136 studies and 22,094 patients made by Buchwald et al.(6) 
revealed an overall resolution of hypertension of 75.4%. In a 
review of 19 studies carried out by Maggard et al.(19) resolu-
tion rates varying from 25% to 75% were observed. According 
to most studies, hypertension control appears to be so linked 
to improvement on insulin sensitivity and proinflammatory 
state as to proper weight loss(11, 15, 16, 27). Previous Brazilian 
reports have shown similar results(9, 21).
Among the factors statistically associated with hyperten-
sion resolution in this sample, there were some related to 
insulin sensitivity (HOMA-IR, preoperative fasting insulin), 
others to hypertension severity (anti-hypertensive usage, 
hypertension duration) and still others directly linked to 
ponderal status (body mass index, percentage of  excess 
weight loss). This finding clearly reinforces the complex 
pathophysiology of  hypertension and its mechanisms of 
resolution after RYGB.
CONCLUSION
There was an important impact of RYGB on hyperten-
sion evolution in diabetic patients, thus this operation may 
be considered a safe and effective therapeutic option within 
this group.
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RESUMO – Contexto - A hipertensão arterial é uma patologia frequente na prática clínica e sua associação ao diabetes mellitus tipo 2 é amplamente 
conhecida. A baixa adesão ao tratamento clínico comumente leva a resultados precários. A cirurgia bariátrica é capaz de promover precocemente 
índices elevados de resolução de ambas as morbidades. Objetivo - Descrever a evolução da hipertensão arterial após o bypass gástrico em Y-de-Roux 
em indivíduos diabéticos. Metodos - Estudo descritivo observacional de coorte histórica envolvendo 90 indivíduos com hipertensão e diabetes que 
foram submetidos ao bypass gástrico em Y-de-Roux, avaliados antes e após o procedimento. Resultados - Foi observado índice de resolução da hi-
pertensão de 85.6% associado a grande redução na utilização de anti-hipertensivos. O tempo médio de resolução foi de 3.2 meses. A resolução esteve 
associada ao modelo de avaliação homeostática (HOMA) – resistência insulínica, insulina basal pré-operatória, uso de anti-hipertensivos, tempo 
de hipertensão, índice de massa corpórea e percentual de perda do excesso de peso. A resolução da hipertensão não foi associada estatisticamente 
à remissão do diabetes na amostra estudada. Conclusão - O bypass gástrico em Y-de-Roux foi uma opção terapêutica segura e eficiente para levar à 
resolução da hipertensão em pacientes diabéticos.
DESCRITORES - Hipertensão. Diabetes Mellitus. Anastomose em Y-de-Roux. Derivação Gástrica. Cirurgia Bariátrica. Obesidade.
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